Eris Lifesciences Limited (BOM:540596)

Eris Lifesciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	6,195	3,518	3,921	3,822	4,061
Depreciation & Amortization	2,795	3,124	1,797	1,144	626.21
Other Amortization	-	30.6	28.2	26.58	20.84
Loss (Gain) From Sale of Assets	0.4	9.2	21.4	20.18	42.54
Loss (Gain) From Sale of Investments	-6.8	-30	-93.8	-69.33	-167.61
Loss (Gain) on Equity Investments	-0.9	-0.6	-	-	-
Stock-Based Compensation	80	91.3	7.5	31.21	13.55
Provision & Write-off of Bad Debts	-107	-	-	0.67	0.02
Other Operating Activities	1,004	2,648	166.8	-302.45	-515.03
Change in Accounts Receivable	-2,103	-91.1	-570.9	-1,171	-204.8
Change in Inventory	-1,007	-943.6	-169.4	47.44	-234.45
Change in Accounts Payable	-31.6	679.4	909.8	-104.97	151.59
Change in Other Net Operating Assets	-1,439	1,615	-1,157	-526.45	-11.35
Operating Cash Flow	5,380	10,650	4,860	2,917	3,783
Operating Cash Flow Growth	-49.48%	119.13%	66.59%	-22.88%	0.77%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-2,969	-1,550	-1,292	-8,414	-1,210
Sale of Property, Plant & Equipment	0.9	3.7	-	1.37	7.58
Cash Acquisitions	-100	-11,690	-5,668	-6,555	-
Investment in Securities	-284.3	-484.3	484.1	4,904	-1,881
Other Investing Activities	-342.6	12,923	-12,053	35.61	49.32
Investing Cash Flow	-3,695	-799.7	-18,545	-9,821	-3,196

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	530	-	-	-	-
Long-Term Debt Issued	1,173	14,364	16,231	11,678	450.01
Total Debt Issued	1,703	14,364	16,231	11,678	450.01
Long-Term Debt Repaid	-2,950	-18,424	-1,603	-3,587	-115.01
Total Debt Repaid	-2,950	-18,424	-1,603	-3,587	-115.01
Net Debt Issued (Repaid)	-1,247	-4,059	14,628	8,091	335
Issuance of Common Stock	44.8	72.2	45.4	22.78	71.96
Common Dividends Paid	-	-1,001	-	-999.11	-816.23
Other Financing Activities	-1,933	-3,826	-875.7	-234.3	-37.72
Financing Cash Flow	-3,135	-8,813	13,798	6,880	-446.99

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Miscellaneous Cash Flow Adjustments	-	17.7	269.6	74.9	-
Net Cash Flow	-1,450	1,055	382.3	51.52	139.55

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	2,411	9,100	3,569	-5,497	2,572
Free Cash Flow Growth	-73.50%	155.01%	-	-	-26.42%
Free Cash Flow Margin	7.74%	31.61%	17.92%	-33.08%	19.40%
Free Cash Flow Per Share	17.62	66.77	26.21	-40.37	18.93
Levered Free Cash Flow	-301.18	6,527	2,357	-6,892	1,623
Unlevered Free Cash Flow	903.01	7,973	2,887	-6,729	1,649

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	1,933	1,451	773	234.3	38.5
Cash Income Tax Paid	1,244	978.8	1,008	772.08	832.85
Change in Working Capital	-4,580	1,260	-987.4	-1,755	-299.01

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error